What is HC Wainwright’s Estimate for RYTM FY2025 Earnings?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a note issued to investors on Monday, December 22nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($3.13) per share for the year, down from their prior forecast of ($3.09). HC Wainwright has a “Buy” rating and a $123.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.77) EPS.

A number of other brokerages have also weighed in on RYTM. Oppenheimer lowered shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 5th. Citizens Jmp increased their price target on Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the company a “market outperform” rating in a research note on Friday, December 12th. Citigroup reissued an “outperform” rating on shares of Rhythm Pharmaceuticals in a report on Friday, December 12th. Needham & Company LLC upped their target price on Rhythm Pharmaceuticals from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Wall Street Zen downgraded Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.47.

Rhythm Pharmaceuticals Price Performance

RYTM stock opened at $112.35 on Wednesday. The company has a 50 day simple moving average of $107.01 and a 200 day simple moving average of $95.09. The stock has a market cap of $7.50 billion, a price-to-earnings ratio of -36.24 and a beta of 1.96. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.The company had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.71 million.

Institutional Trading of Rhythm Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Swiss Life Asset Management Ltd acquired a new stake in Rhythm Pharmaceuticals during the 3rd quarter valued at approximately $249,000. CIBC Bancorp USA Inc. bought a new stake in shares of Rhythm Pharmaceuticals in the 3rd quarter valued at $562,000. Centaurus Financial Inc. acquired a new stake in shares of Rhythm Pharmaceuticals during the third quarter worth $241,000. Captrust Financial Advisors increased its position in shares of Rhythm Pharmaceuticals by 4.5% during the third quarter. Captrust Financial Advisors now owns 18,258 shares of the company’s stock worth $1,844,000 after buying an additional 787 shares during the period. Finally, Cim Investment Management Inc. bought a new position in Rhythm Pharmaceuticals during the third quarter worth $302,000.

Insiders Place Their Bets

In other news, insider Joseph Shulman sold 9,748 shares of the stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $115.24, for a total value of $1,123,359.52. Following the completion of the sale, the insider owned 8,509 shares of the company’s stock, valued at approximately $980,577.16. This represents a 53.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the transaction, the insider owned 20,814 shares of the company’s stock, valued at $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,350 shares of company stock valued at $3,436,340 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.